Ca 2+ entry mode of Na +/Ca 2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction

European Heart Journal

Volumn 33, Issue 11, 2012, Pages 1408-1416

  Kamimura, Daisuke ^a,b,c   Ohtani, Tomohito ^a   Sakata, Yasushi ^a   Mano, Toshiaki ^a,b   Takeda, Yasuharu ^a,b   Tamaki, Shunsuke ^a,b,d   Omori, Yosuke ^a,b   Tsukamoto, Yasumasa ^a,b   Furutani, Kazuharu ^a,d   Komiyama, Yutaka ^e   Yoshika, Masamichi ^e   Takahashi, Hakuo ^e   Matsuda, Toshio ^d   Baba, Akemichi ^d   Umemura, Satoshi ^c   Miwa, Takeshi ^b   Komuro, Issei ^a   Yamamoto, Kazuhiro ^a,d  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Diastole; Digitalis like factors; Fibrosis; Heart failure; Na + Ca 2+ exchanger

Indexed keywords

2 [4 (2,5 DIFLUOROBENZYLOXY)PHENOXY] 5 ETHOXYANILINE; CALCIUM; DIGITALIS LIKE FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OUABAIN; PROLINE; SODIUM CALCIUM EXCHANGE PROTEIN; CARDENOLIDE; DIGOXIN LIKE FACTORS; DIGOXIN-LIKE FACTORS; SAPONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG TARGETING; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEMODYNAMIC MONITORING; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPRAGUE DAWLEY RAT; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; URINARY EXCRETION; ANIMAL; DRUG ANTAGONISM; FIBROSIS; HEART STROKE VOLUME; HEART VENTRICLE; HISTOLOGY; METABOLISM; MYOFIBROBLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; TIBIA; URINE;

ANIMALS; CALCIUM; CARDENOLIDES; FIBROSIS; HEART FAILURE; HEART VENTRICLES; MYOFIBROBLASTS; OUABAIN; RATS; RATS, INBRED DAHL; RATS, SPRAGUE-DAWLEY; SAPONINS; SODIUM-CALCIUM EXCHANGER; STROKE VOLUME; TIBIA;

EID: 84861802412     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr106     Document Type: Article

References (32)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259. (Pubitemid 44079340)
2. Masuyama T, Yamamoto K, Sakata Y, Doi R, Nishikawa N, Kondo H, Ono K, Kuzuya T, Sugawara M, Hori M. Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol 2000;36: 2333-2338.
3. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, Miwa T, Sugawara M, Yamaguchi Y, Ookawara T, Suzuki K, Hori M. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002;55:76-82. (Pubitemid 34615941)
4. Manunta P, Stella P, Rivera R, Ciurlino D, Cusi D, Ferrandi M, Hamlyn JM, Bianchi G. Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Hypertension 1999;34:450-456. (Pubitemid 29426762)
5. Quintas LE, Pierre SV, Liu L, Bai Y, Liu X, Xie ZJ. Alterations of Na(+)/K(+)-ATPase function in caveolin-1 knockout cardiac fibroblasts. J Mol Cell Cardiol 2010;49:525-531.
6. Liu X, Sun SQ, Hassid A, Ostrom RS. cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in cardiac fibroblasts. Mol Pharmacol 2006; 70:1992-2003. (Pubitemid 44771915)
7. Elkareh J, Kennedy DJ, Yashaswi B, Vetteth S, Shidyak A, Kim EG, Smaili S, Periyasamy SM, Hariri IM, Fedorova L, Liu J, Wu L, Kahaleh MB, Xie Z, Malhotra D, Fedorova OV, Kashkin VA, Bagrov AY, Shapiro JI. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 2007;49:215-224. (Pubitemid 46360363)
8. Iwamoto T, Kita S, Zhang J, Blaustein MP, Arai Y, Yoshida S, Wakimoto K, Komuro I, Katsuragi T. Salt-sensitive hypertension is triggered by Ca2+ entry via Na +Ca2+ exchanger type-1 in vascular smooth muscle. Nat Med 2004;10: 1193-1199. (Pubitemid 39540435)
9. Kometiani P, Li J, Gnudi L, Kahn BB, Askari A, Xie Z. Multiple signal transduction pathways link Na +K+-ATPase to growth-related genes in cardiac myocytes. The roles of Ras and mitogen-activated protein kinases. J Biol Chem 1998;273: 15249-15256. (Pubitemid 28272826)
10. Tian J, Gong X, Xie Z. Signal-transducing function of Na+-K+-ATPase is essential for ouabain's effect on [Ca2+]i in rat cardiac myocytes. Am J Physiol 2001;281: H1899-H1907.
11. Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, Iwao H. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001;103: 148-154. (Pubitemid 32050450)
12. Matsuda T, Arakawa N, Takuma K, Kishida Y, Kawasaki Y, Sakaue M, Takahashi K, Takahashi T, Suzuki T, Ota T, Hamano-Takahashi A, Onishi M, Tanaka Y, Kameo K, Baba A. SEA0400, a novel and selective inhibitor of the Na+-Ca2+ exchanger, attenuates reperfusion injury in the in vitro and in vivo cerebral ischemic models. J Pharmacol Exp Ther 2001;298:249-256. (Pubitemid 32574534)
13. Borbely A, van der Velden J, Papp Z, Bronzwaer JGF, Edes I, Stienen GJM, Paulus WJ. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005; 111:774-781. (Pubitemid 40250638)
14. Sakata Y, Masuyama T, Yamamoto K, Doi R, Mano T, Kuzuya T, Miwa T, Takeda H, Hori M. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-independent hypertrophy. J Am Coll Cardiol 2001;37:293-299. (Pubitemid 32051753)
15. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002;105: 2512-2517. (Pubitemid 34568973)
16. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMPreserved Trial. Lancet 2003;362:777-781. (Pubitemid 37093918)
17. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-2345. (Pubitemid 44453578)
18. Balzan S, Neglia D, Ghione S, D'Urso G, Baldacchino MC, Montali U, L'Abbate A. Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction. Eur J Heart Fail 2001;3:165-171. (Pubitemid 32216656)
19. Goto A, Yamada K, Nagoshi H, Terano Y, Omata M. Stress-induced elevation of ouabainlike compound in rat plasma and adrenal. Hypertension 1995;26: 1173-1176.
20. Bauer N, Müller-Ehmsen J, Krämer U, Hambarchian N, Zobel C, Schwinger RH, Neu H, Kirch U, Grünbaum EG, Schoner W. Ouabain-like compound changes rapidly on physical exercise in humans and dogs: effects of beta-blockade and angiotensin-converting enzyme inhibition. Hypertension 2005;45:1024-1028. (Pubitemid 40628954)
21. Selden R, Margolies MN, Smith TW. Renal and gastrointestinal excretion of ouabain in dog and man. J Pharmacol Exp Ther 1974;188:615-623.
22. Yoshika M, Komiyama Y, Konishi M, Akizawa T, Kobayashi T, Date M, Kobatake S, Masuda M, Masaki H, Takahashi H. Novel digitalis-like factor, marinobufotoxin, isolated from cultured Y-1 cells, and its hypertensive effect in rats. Hypertension 2007;49:209-214. (Pubitemid 46360362)
23. Peng M, Huang L, Xie Z, Huang W-H, Askari A. Partial inhibition of Na/K-ATPase by ouabain induces the Ca-dependent expressions of early-response genes in cardiac myocytes. J Biol Chem 1996;271:10372-10378.
24. Li M, Martin A, Wen C, Turner SW, Lewis LK, Whitworth JA. Long-term ouabain administration does not alter blood pressure in conscious Sprague-Dawley rats. Clin Exp Pharmacol Physiol 1995;22:919-923. (Pubitemid 26020862)
25. Sakamoto K, Owada Y, Shikama Y, Wada I, Waguri S, Iwamoto T, Kimura J. Involvement of Na +Ca2+ exchanger in migration and contraction of rat cultured tendon fibroblasts. J Physiol (Lond) 2009;587:5345-5359.
26. Weber CR, Piacentino V, Houser SR, Bers DM. Dynamic regulation of sodium/calcium exchange function in human heart failure. Circulation 2003;108: 2224-2229. (Pubitemid 37363039)
27. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
28. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27: 178-186. (Pubitemid 43069034)
29. Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol 2007; 293:C509-C536.
30. Yamamoto K, Sakata Y, Ohtani T, Takeda Y, Mano T. Heart failure with preserved ejection fraction. Circ J 2009;73:404-410.
31. Acsai K, Kun A, Farkas AS, Fulop F, Nagy N, Balazs M, Szentandrassy N, Nanasi PP, Papp JG, Varro A, Toth A. Effect of partial blockade of the Na(+)/Ca(2+)-exchanger on Ca(2+) handling in isolated rat ventricular myocytes. Eur J Pharmacol 2007;576:1-6. (Pubitemid 47588247)
32. Reuter H, Henderson SA, Han T, Matsuda T, Baba A, Ross RS, Goldhaber JI, Philipson KD. Knockout mice for pharmacological screening: testing the specificity of Na+-Ca2+ exchange inhibitors. Circ Res 2002;91:90-92. (Pubitemid 34827218)